58 related articles for article (PubMed ID: 8863547)
1. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.
Dinney CP; Fisher MB; Navai N; O'Donnell MA; Cutler D; Abraham A; Young S; Hutchins B; Caceres M; Kishnani N; Sode G; Cullen C; Zhang G; Grossman HB; Kamat AM; Gonzales M; Kincaid M; Ainslie N; Maneval DC; Wszolek MF; Benedict WF
J Urol; 2013 Sep; 190(3):850-6. PubMed ID: 23507396
[TBL] [Abstract][Full Text] [Related]
2. Bacillus Calmette-Guérin-induced kidney granulomas.
Zhang X; Lian H; Song X; Li J
Kidney Int; 2024 May; 105(5):1131. PubMed ID: 38642981
[No Abstract] [Full Text] [Related]
3. Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
D'Andrea D; Gontero P; Shariat SF; Soria F
Transl Androl Urol; 2019 Feb; 8(1):85-93. PubMed ID: 30976572
[TBL] [Abstract][Full Text] [Related]
4. A comparative study between full-dose and half-dose intravesical immune bacille Calmette-Guérin injection in the management of superficial bladder cancer.
Kandeel W; Abdelal A; Elmohamady BN; Sebaey A; Elshaaer W; Elbarky E; Abdelwahab O
Arab J Urol; 2015 Dec; 13(4):233-7. PubMed ID: 26609439
[TBL] [Abstract][Full Text] [Related]
5. Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG.
Zachos I; Tzortzis V; Mitrakas L; Samarinas M; Karatzas A; Gravas S; Vandoros GP; Melekos MD; Papavassiliou AG
Tumour Biol; 2014 May; 35(5):4185-9. PubMed ID: 24375197
[TBL] [Abstract][Full Text] [Related]
6. Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison.
Inamoto T; Ubai T; Nishida T; Fujisue Y; Katsuoka Y; Azuma H
Urol Ann; 2013 Jan; 5(1):7-12. PubMed ID: 23662001
[TBL] [Abstract][Full Text] [Related]
7. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.
Vacchelli E; Galluzzi L; Eggermont A; Fridman WH; Galon J; Sautès-Fridman C; Tartour E; Zitvogel L; Kroemer G
Oncoimmunology; 2012 Sep; 1(6):894-907. PubMed ID: 23162757
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of genitourinary malignancies.
Inamoto T; Azuma H
J Oncol; 2012; 2012():397267. PubMed ID: 22481927
[TBL] [Abstract][Full Text] [Related]
9. The optimal management of T1 high-grade bladder cancer.
Nepple KG; O'Donnell MA
Can Urol Assoc J; 2009 Dec; 3(6 Suppl 4):S188-92. PubMed ID: 20019983
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of cystocopically pseudotumoral lesions (inflammation/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG.
Pieras-Ayala E; Palou-Redorta J; Tomero-Ruiz JI; Montlleó-González M; Salvador-Bayarri J; Vicente-Rodríguez J
Int Urol Nephrol; 2001; 33(3):469-72. PubMed ID: 12230274
[TBL] [Abstract][Full Text] [Related]
11. The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients.
Reyes E; Carballido J; Manzano L; Moltó L; Olivier C; Alvarez-Mon M
Br J Cancer; 1999 Mar; 79(7-8):1162-7. PubMed ID: 10098752
[TBL] [Abstract][Full Text] [Related]
12. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.
Losa A; Hurle R; Lembo A
J Urol; 2000 Jan; 163(1):68-71; discussion 71-2. PubMed ID: 10604316
[TBL] [Abstract][Full Text] [Related]
13. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
14. Low dose BCG as adjuvant therapy for superficial bladder cancer and literature review.
Cheng CW; Ng MT; Chan SY; Sun WH
ANZ J Surg; 2004 Jul; 74(7):569-72. PubMed ID: 15230793
[TBL] [Abstract][Full Text] [Related]
15. Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.
Kwak C; Ku JH; Park JY; Lee E; Lee SE; Lee C
J Urol; 2004 Jan; 171(1):149-52. PubMed ID: 14665864
[TBL] [Abstract][Full Text] [Related]
16. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
[TBL] [Abstract][Full Text] [Related]
17. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
